Cdc37 Antibody (C-11): sc-17758
- Cdc37 Antibody (C-11) is a mouse monoclonal IgG2b κ, cited in 9 publications, provided at 200 µg/ml
- raised against amino acids 108-378 of Cdc37 of human origin
- recommended for detection of Cdc37 of human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Cdc37 Antibody (C-11). This work is in progress.
Cdc37 Antibody (C-11) is a mouse monoclonal IgG2b antibody that detects Cdc37 in human samples through various applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA). Cdc37 monoclonal antibody (C-11) recognizes a protein that plays a crucial role in cell cycle progression by facilitating the formation of cyclin-dependent kinase (Cdk) complexes, particularly the Cdk4/cyclin D1 complex, essential for the transition from G1 phase to S phase of the cell cycle. Anti-Cdc37 monoclonal antibody (C-11) targets a protein that ensures proper cell division and proliferation, fundamental processes in growth and development. Cdc37 (C-11) antibody detects a protein that forms a stable complex with heat shock protein 90 (Hsp90), important for the stability and activity of various client proteins, including several kinases. Cdc37 monoclonal antibody (C-11) identifies a protein that contributes to the regulation of cellular signaling pathways, making Cdc37 a significant player in cancer biology and diseases characterized by dysregulated cell growth.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Cdc37 Antibody (C-11) References:
- Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. | Smith, JR., et al. 2015. Oncogene. 34: 15-26. PMID: 24292678
- How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches. | Verba, KA. and Agard, DA. 2017. Trends Biochem Sci. 42: 799-811. PMID: 28784328
- Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. | Li, T., et al. 2018. J Hematol Oncol. 11: 59. PMID: 29699578
- Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. | Wang, L., et al. 2019. Sci Adv. 5: eaax2277. PMID: 31555737
- Therapeutic Potential of the Hsp90/Cdc37 Interaction in Neurodegenerative Diseases. | Gracia, L., et al. 2019. Front Neurosci. 13: 1263. PMID: 31824256
- Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer. | Wang, L., et al. 2022. Med Res Rev. 42: 156-182. PMID: 33846988
- Thioredoxin-1 inhibits the activation of IRE1 by targeting Hsp90/p-Cdc37 chaperone complex in Parkinson disease. | Zeng, X., et al. 2023. Ageing Res Rev. 90: 102000. PMID: 37437766
- Ginsenoside Rg5 enhances the radiosensitivity of lung adenocarcinoma via reducing HSP90-CDC37 interaction and promoting client protein degradation. | Bai, H., et al. 2023. J Pharm Anal. 13: 1296-1308. PMID: 38174116
- Structural dynamics of RAF1-HSP90-CDC37 and HSP90 complexes reveal asymmetric client interactions and key structural elements. | Finci, LI., et al. 2024. Commun Biol. 7: 260. PMID: 38431713
- Allosteric CDC37 Inhibitor Disrupts Chaperone Complex to Block CDK4/6 Maturation. | Zhang, L., et al. 2025. Angew Chem Int Ed Engl. 64: e202413618. PMID: 39582167
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdc37 Antibody (C-11) | sc-17758 | 200 µg/ml | $322.00 |